Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
VANCOUVER, British Columbia, March 13, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Wednesday, March 15, 2017 at 8:30 a.m. Eastern Time to provide a business update and review preliminary fourth quarter and full year 2016 financial results.
To participate, please dial (866) 516-3002 (domestic) or (760) 298-5082 (international). A live webcast will be available in the “Investors” section of Novelion’s website, www.novelion.com, and a replay will be available for 90 days after the conclusion of the event.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
